Chemistry of Heterocyclic Compounds

, Volume 47, Issue 12, pp 1502–1508 | Cite as

Synthesis and antitumor activity of 3-[(methyl)bis(5-trialkylsilyl-furan-2-yl)silyl]propylamines

  • L. IgnatovichEmail author
  • V. Romanov
  • J. Spura
  • J. Popelis
  • I. Domracheva
  • I. Shestakova

Novel 3-[(methyl)bis(5-trialkylsilylfuran-2-yl)silyl]propylamines have been synthesized by a hydrosilylation reaction of aliphatic and heterocyclic N-allylamines in the presence of the Speier's catalyst. The effects of the structure of the amine and the alkyl substituent at the silicon atom on the cytotoxicity of the compounds have been studied.


3-[(methyl)bis(5-trialkylsilylfuran-2-yl)silyl]propylamines cytotoxicity hydrosilylation 


  1. 1.
    A. Kleemann, J. Engel, B. Kutscher, and D. Reichert, Pharmaceutical Substances, Thieme, Stuttgart and New York (2009).Google Scholar
  2. 2.
    D. A. Erlanson and W. Jahnke (editors), Fragment-Based Approaches in Drug Discovery, Wiley-VCH, Weinheim (2006), p. 91.Google Scholar
  3. 3.
    C. L. Bethea, S. J. Mirkes, A. Su, and D. Michelson, Psychoneuroendocrinology, 27, 431 (2002).CrossRefGoogle Scholar
  4. 4.
    C. J. Fabian, B. F. Kimler, J. Anderson, O. W. Tawfik, M. S. Mayo, W. E. Burak, Jr., J. A. O’Shaughnessy, K. S. Albain, D. M. Hyams, G. T. Budd, P. A. Ganz, E. R. Sauter, S. W. Beenken, W. E. Grizzle, J. P. Fruehauf, D. W. Arneson, J. W. Bacus, M. D. Lagios, K. A. Johnson, and D. Browne, Clin. Cancer Res., 10, 5403 (2004).CrossRefGoogle Scholar
  5. 5.
    P. N. Munster, Expert Opin. Invest. Drugs, 15, 317 (2006).CrossRefGoogle Scholar
  6. 6.
    M. Blagosklonny, Trends Pharmacol. Sci., 26, 77 (2005).CrossRefGoogle Scholar
  7. 7.
    F. Mollinedo, Expert Opin. Ther. Pat., 17, 385 (2007).CrossRefGoogle Scholar
  8. 8.
    S. R. Vink, A. H. van der Luit, J. B. Klarenbeek, M. Verheij, and W. J. van Blitterswijk, Biochem. Pharmacol., 74, 1456 (2007).CrossRefGoogle Scholar
  9. 9.
    A. Huston, X. Leleu, X. Jia, A.-S. Moreau, H. T. Ngo, J. Runnels, J. Anderson, Y. Alsayed, A. Roccaro, S. Vallet, E. Hatjiharissi, Y.-T. Tai, P. Sportelli, N. Munshi, P. Richardson, T. Hideshima, D. G. Roodman, K. C. Anderson, and I. M. Ghobrial, Clin. Cancer Res., 14, 865 (2008).CrossRefGoogle Scholar
  10. 10.
    P. Norman, Curr. Opin. Invest. Drugs (BioMed Cent.), 2, 428 (2001).Google Scholar
  11. 11.
    J. A. McIntyre, J. Castaner, and P. A. Lesson, Drugs Future, 30, 771 (2005).CrossRefGoogle Scholar
  12. 12.
    M. Muhsin, J. Graham, and P. Kirkpatrick, Nat. Rev. Drug Discovery, 2, 515 (2003).CrossRefGoogle Scholar
  13. 13.
    J. A. Smith, A. Gaikwad, J. Yu, J. K. Wolf, J. Brown, L. M. Ramondetta, and C. F. Stewart, Cancer Chemother. Pharmacol., 62, 51 (2008).CrossRefGoogle Scholar
  14. 14.
    A. J. Barker, K. H. Gibson, W. Grundy, A. A. Godfrey, J. J. Barlow, M. P. Healy, J. R. Woodburn, S. E. Ashton, B. J. Curry, L. Scarlett, L. Henthorn, and L. Richards, Bioorg. Med. Chem. Lett., 11, 1911 (2001).CrossRefGoogle Scholar
  15. 15.
    H. Kantarjian, E. Jabbour, J. Grimley, and P. Kirkpatrick, Nat. Rev. Drug Discovery, 5, 717 (2006).CrossRefGoogle Scholar
  16. 16.
    S. L. Martin, A. McDowell, J. F. Lynas, J. Nelson, and B. Walker, J. Pharm. Pharmacol., 53, 333 (2001).CrossRefGoogle Scholar
  17. 17.
    A. R. Lera, W. Bourguet, L. Altucci, and H. Gronemeyer, Nat. Rev. Drug Discovery, 6, 811 (2007).CrossRefGoogle Scholar
  18. 18.
    I. R. Radford, Curr. Opin. Invest. Drugs (BioMed Cent.), 3, 492 (2002).Google Scholar
  19. 19.
    A. Bilir, B. Erguven, G. Oktem, A. Ozdemir, A. Uslu, E. Aktas, and B. Bonavina, Int. J. Oncol., 32, 829 (2008).Google Scholar
  20. 20.
    W. Shelly, M. W. Draper, V. Krishnan, M. Wong, and R. B. Jaffe, Obstet. Gynecol. Surv., 63, 163 (2008).Google Scholar
  21. 21.
    C. K. Baumann and M. Castiglione-Gertsch, Drugs, 67, 2335 (2007).CrossRefGoogle Scholar
  22. 22.
    M. G. Voronkov, G. I. Zelchan, and E. Lukevics, Silicon and Life [in Russian], Riga (1978).Google Scholar
  23. 23.
    E. Lukevits, V. Lūse, I. Zicmane, E. Liepiņš, M. Trušule, S. Ģērmane, I. Augustāne, V. N. Verovsky, N. G. Prodanchuk, S. E. Deineka, and V. N. Nivalov, Khim. Geterotsikl. Soedin., 1653 (1991). [Chem. Heterocycl. Comp., 27, 1328 (1991)].Google Scholar
  24. 24.
    L. Ignatovich, V. Muravenko, I. Shestakova, I. Domrachova, J. Popelis, and E. Lukevics, Appl. Organomet. Chem., 24, 158 (2010).CrossRefGoogle Scholar
  25. 25.
    L. Ignatovich, V. Romanov, I. Shestakova, I. Domrachova, J. Popelis, and E. Lukevics, Khim. Geterotsikl. Soedin., 1791 (2009). [Chem. Heterocycl. Comp., 45, 1441 (2009)].Google Scholar
  26. 26.
    E. Lukevics and L. Ignatovich, in: M. Gielen and E. R. T. Tiekink (editors), Metallotherapeutic Drugs and Metal-Based Diagnostic Agents. The Use of Metals in Medicine, John Wiley and Sons, Chichester (2005), p. 83.CrossRefGoogle Scholar
  27. 27.
    W. Bains and R. Tacke, Curr. Opin. Drug Discovery Dev., 6, 526 (2003).Google Scholar
  28. 28.
    M. Mägi, E. Lippmaa, E. Lukevics, and N. P. Erčak, Org. Magn. Reson., 9, 297 (1977).CrossRefGoogle Scholar
  29. 29.
    Report of the International Workshop on in vitro Methods for Assessing Acute Systemic Toxicity, NIH Publ. No: 01-4499 ( 2001), p. 12.Google Scholar
  30. 30.
    D. J. Fast, R. C. Lynch, and R. W. Leu, J. Leukocyte Biol., 52, 255 (1992).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2012

Authors and Affiliations

  • L. Ignatovich
    • 1
    Email author
  • V. Romanov
    • 1
  • J. Spura
    • 1
  • J. Popelis
    • 1
  • I. Domracheva
    • 1
  • I. Shestakova
    • 1
  1. 1.Latvian Institute of Organic SynthesisRigaLatvia

Personalised recommendations